Publication: 328

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1
      QxMD      Google Scholar   
Citation:
J Thorac Oncol vol 3 (5) 516-520
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35090, U10 CA060276, CA-35195, U10 CA037404, N01 CA035119, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-60276, CA-35113, U10 CA035113, P30 CA015083, CA-52654, CA-63848, U10 CA063849, U10 CA035431, U10 CA035119, CA-37417, CA-35269, U10 CA052654, U10 CA025224, U10 CA035090, CA-15083, CA-35267, CA-63849, N01 CA015083, U10 CA035103  
Corr. Author:
 
Authors:
                         
Networks:
 
Study
NCCTG-N044B
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Article